It is clear that more than two third of breast cancers express EGFR abnormally [4], and 90% of pancreatic cancer patients, of which the 5-year survival rate is less than 5%, overly express EGFR or it's ligands, such as TGFα and EGF [5–6]. Here, EGFR is linked to breast cancer.